Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis.
Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis.
复制标题
DOI：
10.1080/10408363.2018.1425976
复制
发表时间：
2018-05
影响因子：
10
通讯作者：
Zhang JXJ
中科院分区：
文献类型：
--
作者：
Tadimety A;Closson A;Li C;Yi S;Shen T;Zhang JXJ
液体活检作为一种通过患者液体样本来深入了解疾病动态的微创方法，在癌症诊断、预后和监测方面越来越受欢迎。虽然许多技术已经在研究实验室中开发和验证，但也有人推动将这些技术扩展到其他临床环境和作为床旁设备。在这篇综述中，我们讨论和评估基于微芯片技术的循环肿瘤细胞（CTC），外泌体，循环肿瘤核酸（ctNA）的捕获，检测和分析。这样的集成系统简化了否则多步骤的手动操作，以获得样品到答案的定量。此外，疾病生物标志物的分析适合于护理点环境，因为易于使用、样品和试剂的低消耗以及高通量。我们还涵盖了生物标志物的基础知识及其在生物液体样本中的检测，适用于芯片上液体活检。我们专注于以高时空分辨率处理小患者样本的新兴技术，并通过简单工作流程中的芯片生物标志物传感和下游分子分析获得具有临床意义的结果。这篇重要的评论是为那些有兴趣在各种环境中开发用于液体活检的捕获、检测和分析平台的技术的人提供的资源。
Liquid biopsy, as a minimally invasive method of gleaning insight into the dynamics of diseases through a patient fluid sample, has been growing in popularity for cancer diagnosis, prognosis, and monitoring. While many technologies have been developed and validated in research laboratories, there has also been a push to expand these technologies into other clinical settings and as point of-care devices. In this review we discuss and evaluate microchip-based technologies for circulating tumor cell (CTC), exosome, and circulating tumor nucleic acid (ctNA) capture, detection, and analysis. Such integrated systems streamline otherwise multiple-step, manual operations to get a sample-to-answer quantitation. In addition, analysis of disease biomarkers is suited to point of care settings because of ease of use, low consumption of sample and reagents, and high throughput. We also cover the basics of biomarkers and their detection in biological fluid samples suitable for liquid biopsy on-chip. We focus on emerging technologies that process a small patient sample with high spatial-temporal resolution and derive clinically meaningful results through on-chip biomarker sensing and downstream molecular analysis in a simple workflow. This critical review is meant as a resource for those interested in developing technologies for capture, detection, and analysis platforms for liquid biopsy in a variety of settings.
登录
查看更多内容
影响因子：
16.6
作者：
De Mattos-Arruda L;Mayor R;Ng CKY;Weigelt B;Martínez-Ricarte F;Torrejon D;Oliveira M;Arias A;Raventos C;Tang J;Guerini-Rocco E;Martínez-Sáez E;Lois S;Marín O;de la Cruz X;Piscuoglio S;Towers R;Vivancos A;Peg V;Ramon y Cajal S;Carles J;Rodon J;González-Cao M;Tabernero J;Felip E;Sahuquillo J;Berger MF;Cortes J;Reis-Filho JS;Seoane J
通讯作者：
Seoane J
影响因子：
6.1
作者：
Earhart CM;Hughes CE;Gaster RS;Ooi CC;Wilson RJ;Zhou LY;Humke EW;Xu L;Wong DJ;Willingham SB;Schwartz EJ;Weissman IL;Jeffrey SS;Neal JW;Rohatgi R;Wakelee HA;Wang SX
通讯作者：
Wang SX
影响因子：
3.4
作者：
Cree IA;Deans Z;Ligtenberg MJ;Normanno N;Edsjö A;Rouleau E;Solé F;Thunnissen E;Timens W;Schuuring E;Dequeker E;Murray S;Dietel M;Groenen P;Van Krieken JH;European Society of Pathology Task Force on Quality Assurance in Molecular Pathology;Royal College of Pathologists
通讯作者：
Royal College of Pathologists
影响因子：
4.6
作者：
Chen P;Huang YY;Hoshino K;Zhang JX
通讯作者：
Zhang JX
DOI：
10.1196/annals.1448.050
发表时间：
2008-01-01
期刊：
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V
影响因子：
--
作者：
Gahan, Peter B.;Swaminathan, R.
通讯作者：
Swaminathan, R.